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A large body of experimental evidence indicates 
that over-activation of excitatory amino acid (EAA) 
receptors may mediate irreversible neuronal injury 
in a variety of pathologic settings including cerebral 
ischemia, and that the developing brain may be par- 
ticularly susceptible to the adverse effects of EAA 
receptor overactivation. In this article, w e  review 
current information about EAA receptor pharmaco- 
logy and EAA neurotoxicity in the immature brain, 
and summarize recent experimental data indicating 
that EAA contribute to the pathogenesis of perina- 
tal hypoxic-ischemic brain injury. 
introduction 
In the last decade, several seminal observations have 
provided support for the hypothesis that  endoge- 
nous excitatory amino acid (EAA) neurotransmitters 
(e.g., glutamic acid) play a major role in the pathge- 
nesis of hypoxic-ischemic neuronal injury. In vitro, 
in cultured hippocampal neurons, Rothman first 
demonstrated that anoxic neuronal injury was 
dependent on synaptic activity; a substantial body 
of subsequent work confirmed that EAA mediated 
anoxic neuronal injury in vitro (1). Concurrently, in 
experimental animal models of ischemic brain 
injury, a variety of experimental strategies yielded 
complementary evidence that EAA contributed to  
the pathogenesis of irreversible ischemic neuronal 
injury. Important findings included: the recognition 
that regions with high densities of EAA receptors 
were particularly susceptible to ischemic injury (Z), 
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observations that intra-cerebral injection of the com- 
petitive EAA antagonist arninophosphonoheptanoic 
acid (AP7) attenuated acute ischemic neuronal dam- 
age (3) and that preceding deafferentation reduced 
ischemic damage to highly vulnerable hipppocampal 
neurons (4), and results of in vivo microdialysis stud- 
ies that demonstrated directly substantial increases in 
hippocampal extracellular glutamate concentrations 
during cerebral ischemia (5). In the immature ner- 
vous system, Hagberg et al. demonstrated that in 
fetal lambs, cerebral ischemia resulted in marked 
rises in  cortical and striatal glutamate content (6) 
and McDonald et al. showed that treatment with 
the noncompetitive. EAA antagonist MK-801 [ (+)-5- 
methyl-10, 1 1-dihydro-5H-dibenzo-(a,d)-cyclohepten- 
5,lO-imine maleate] was neuroprotective in a model 
of perinatal focal cerebral ischemia (7). 
Current important experimental questions include 
elucidation of the distinct roles of EAA in the patho- 
genesis of neuronal injury after focal and global 
ischemia, development of effective neuroprotective 
interventions based on EAA pharmacology (8,9), and 
understanding the potential adverse effects of drugs 
acting at EAA receptors. In this review, we will pre- 
sent results of recent studies that provide important 
new insights about the potential contributions of 
EAA to perinatal hypoxic-ischemic brain injury. 
Excitatory Amino Acid (EAA) Pharmacology 
A n  understanding of EAA neuropharmacology is an 
essential prerequisite for analysis of the role of EAA 
in the pathogenesis of brain injury and for develop- 
ment of therapeutic strategies based on EAA receptor 
blockade. In theory, it would be possible to modulate 
EAA synaptic function by altering synthesis, release, 
re-uptake of EAA, or receptor activation. Few phar- 
macologic agents with specific pre-synaptic actions 
1 Glossary for Abbreviations 
EAA Excitatory amino acids 
PND Post-natal day 
ECF Extracellular fluid 
HPLC High performance liquid chromatagraphy 
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have been developed, and EAA pharmacology is cur- 
rently focused primarily on analysis of post-synaptic 
receptors. 
Several classsification schemes for EAA receptors 
have been devised, based on their selective responses 
to the agonists N-methyl-D-aspartate (NMDA), quis- 
qualic acid and kainate, and on their signal trans- 
duction mechanisms (ionotropic or metabotropic) 
(1 0-1 2). 
NMDA receptor-channel complex. The NMDA-recep- 
tor channel complex includes the EAA recognition 
site, a voltage-dependent cation channel permeable 
to both sodium and calcium, which, at rest, is 
blocked by magnesium, and a strychnine-insensitive 
glycine receptor that is activated by physiologic con- 
centrations of glycine. Several distinct groups of 
NMDA antagonists, with different loci of action, 
have been identified (13). The NMDA receptor-chan- 
nel complex can be blocked competitively at its ago- 
nist binding site, by compounds such as aminophos- 
phonoheptanoic acid (see Table). Non-competitive 
antagonists such as phencyclidine (PCP) and MK-801 
[ (+)-5-methyl-10, 11-dihydro-5H-dibenzo (a,d) 
cyclohepten-5-10-imine maleate] bind at sites within 
the ion channel, and glycine antagonists (e.g., 7- 
chlorokynurenate) can also functionally block 
NMDA receptor activation (see Table). Distinct bind- 
ing sites for polyamines have also been identified, 
and polyamines appear to be have complex regulato- 
ry influences on NMDA-receptor function (14). 
Many recent studies have evaluated the neuropro- 
tective efficacy of competitive and non-competitive 
NMDA antagonists in experimental animal models 
of ischemic brain injury. Numerous reports have 
demonstrated efficacy in models of focal cerebral 
ischemia (15-1 7), however, other studies attributed 
beneficial effects to non-EAA-mediated effects (18). 
Furthermore, in models of global cerebral ischemia, 
generally, NMDA antagonists have not proven to be 
effective neuroprotective agents (19). 
Another important observation relevant to the 
potential therapeutic actions of NMDA antagonists is 
their potential deleterious effects (20); Olney and 
colleagues first reported that MK-801 induced acute 
vacuolar degeneration in selected cell populations 
and subsequently showed that these degenerative 
changes could be prevented by concurrent adminis- 
tration of anti-cholinergic drugs or diazepam (21). 
Non-NMDA receptors. There are two groups of quis- 
qualate-sensitive receptors, those linked with a 
cation channel and selectively. responsive to the 
agonist alpha-amino-3-hydroxy-5-methyl-4-isoxazole 
propionate (AMPA), and the metabotropic quisqua- 
late receptor (linked with phospholipase C). A dis- 
tinct group of EAA receptors respond selectively 
to kainic acid. The ionotropic receptors are linked 
with cation channels permeable to sodium. Effective 
AMPA receptor antagonists have also recently been 
developed. The systemically administered AMPA 
receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfa- 
moyl-benzo ( f )  quinoxaline (NBQX) is neuroprotec- 
tive in models of global cerebral ischemia in adult 
gerbils and rats (22-24). 
Recent advances in molecular analysis of EAA recep- 
tor encoding genes suggest that there may be con- 
siderably greater diversity in EAA receptor expression 
than is currently discernible pharmacologically. Mul- 
tiple genes encoding EAA receptors or constituent. 
subunits have been cloned, and ontogenetic changes 
in the regional distributions of the mRNAs for sped- 
fic EAA receptor subunits have been identified (25). 
EM-Mediated Neurotoxicity 
A large body of experimental data indicates that 
over-activation of EAA receptors by endogenous or 
exogenous agonists can cause neuronal damage (the 
concept of "excitotoxicity") (26). Increased activation 
of EAA receptors could reflect elevated synaptic con- 
centrations of EAA (because of increased release or 
failure of neuronal or glial re-uptake) or increased 
receptor sensitivity to the agonist. 
Molecular mechanisms of neurotoxicity. The molec- 
ular mechanisms that mediate EAA-induced injury 
have, for the most part, been elucidated in vitro. Cur- 
rent evidence indicates that overwhelming increases 
in free intracellular calcium (attributable to increased 
entry through NMDA and voltage-gated channels 
and inability of mitochondria to compensate) repre- 
sent the final common pathway of EAA-mediated 
injury (27). The blockade of NMDA-induced calcium 
entry by the neuroprotective non-competitive antag- 
onist MK-801 has recently been documented in vivo 
Relevant to understanding EAA-mediated mecha- 
nisms in ischemic injury is the observation that the 
vulnerability of cultured neurons to glutamate neu- 
rotoxicity rises during glucose deprivation, anoxia or 
pharmacologic inhibition of oxidative phosphoryla- 
tion (29), perhaps because of limited adaptive capac- 
ity of metabolically compromised mitochondria to 
rises in free intracellular calcium. In fact, the rela- 
tionship between compromised energy state and sus- 
ceptibility to EAA-mediated injury may be relevant to 
the pathogenesis of irreversible injury in a variety of 
pathologic conditions (for review, see Ref. 30). 
Excessive EAA-receptor activation may have other 
potentially deleterious effects as well. In some cell 
populations, EAA's activate phospholipase A2, and 
stimulate release of arachidonic acid (31). Arachi- 
donic acid has many potential deleterious effects on 
cell membranes; in addition, it may directly suppress 
neuronal and glial EAA re-uptake mechanisms and 
thereby contribute to synaptic EAA accumulation 
(28). 
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Table 1 Drugs acting at excitatory amino acids ( E M )  synapses 











AP-5, AP-7, CPP, CGS-19755 
MK-801, PCP, TCP, dextro- 
methorphan, ketamine 
Kynurenate, 7-chlorokynurenate, 
HA-966, CNQX, DNQX 
Glutamate, AMPA, quis- 
qualate, kainate, ibotenate 






CNQX, DNQX, kynurenate 
Abbreviations 
AMPA Alpha-amino-3-hydroxy-5-rnethyl-4-isoxazole propionate 
APS D (-) -2-amino-5-phosphonovalerate 
AP7 D (4 -2-amino-7-phosphonoheptanoate 
CPP 3 (-1 -2-carboxypiperazin-4-ylpropyl-1 -phosphonate 
CGS- 19755 cis-4-phosphonomethyI-2-piperidine carboxylate 
CNQX 
DNQX 6.7-dinitroquinoxaline-2.3-dione 
HA-966 1 -hydroxy-3-aminopyrrolid-2-one 
M K-80 1 




Trans-ACPD Trans-1 -arninocyclopentane-l,3-dicarboxylate 
6-cyano-7-n itroqui noxa I ine-2.3-dione 
(+)-5-methyl-l0,11 I-dihydro-5H-dibenzo-[a,dl-cyclohepten-5,lO-imine maleate 
1 - [1-(2-thienyl)-cyclohexyl I piperindine 
(32). Recent data suggest that NMDA neurotoxicity 
may also be mediated by activation of ornithine 
decarboxylase, which results in increased polyamine 
synthesis. The polyamine synthesis inhibitor alpha- 
difluoromethylornithine blocked NMDA-induced 
neurotoxicity in vitro (33) and in vivo (34). E M  may 
also stimulate formation of nitric oxide (NO) (35); 
both in viiro and in vivo data suggest that NO may be 
neurotoxic (36).  Treatment with NG-Nitro-L-arginine, 
a compound that blocks NO synthesis, limited the 
severity of injury in an adult rodent model of focal 
ischemic brain injury (37). 
EAA neurotoxicity in the developing brain. Imma- 
ture neurons may be particularly sensitive to  the 
deleterious effects of EAA receptor overactivation. 
The ontogeny of excitotoxicity has been studied by 
histopathologic assessment of brain injury after 
direct intra-cerebral injections of agonists at different 
developmental stages. In contrast with the resistance 
of the immature mammalian brain to kainic acid, 
NMDA neurotoxicity peaks in the early post-natal 
period. The neurotoxicity of NMDA in hippocam- 
pus, striatum and neocortex is maximal in the imma- 
ture rat brain, peaking at postnatal day six to seven 
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Figure 1 Hippocampal glutamate efflux during perinatal 
hypoxia-ischemia: Microdialysis probes were inserted into the 
right hippocampus of PND 7 rats that underwent right carotid 
ligation, followed by exposure to 8% oxygen for two hours 
(n=6, see Ref. 56 for methods). Beginning two hours after 
probe insertion, ten sequential 20 minute dialysis samples 
were collected from each animal. Amino acid content of 
dialysates was quantitated by an HPLC assay. This graph com- 
pares sequential hippocampal glutamate and glutamine efflux 
values, expressed as % baseline, in six animals that under- 
went right carotid artery ligation followed by two hours of 8% 
oxygen exposure. Baseline values were defined as the aver- 
ages from the first three fractions collected in each animal. 
Reproduced from Referece 56, with permission from The 
International Society for Pediatric Research. 
(38,39). Stereotaxic injections of NMDA (5-25 nmol) 
into posterior striatum produce dose-dependent 
injury with neuronal necrosis in striatum and over- 
lying dorsal hippocampus and cortex. At this devel- 
opmental stage, susceptibility to quisqualic acid neu- 
rotoxicity is also relatively high, as compared with 
adult brain (40); yet, NMDA is considerably more 
toxic (100 nmol quisqualate or 10 nmol NMDA elicit 
injury of similar severity) (41). Intracerebral injection 
of glutamate typically results in no injury because of 
rapid neuronal and glial uptake; yet, injections of 
massive doses may also produce small brain lesions 
Enhanced sensitivity of the immature brain to EAA- 
induced toxicity could reflect increased receptor den- 
sity, altered receptor sensitivity (due to age-related 
differences in the molecular constitution of EAA 
receptors), or differences in modulatory or compen- 
satory mechanisms. Autoradiographic receptor bind- 
ing assays indicate that in certain regions (e.g. hip- 
pocampus, globus pallidus), the immature brain has 
a higher density of both NMDA and non-NMDA type 
E M  receptors than adult brain; however, the onto- 
genetic peaks of receptor density and susceptibility to 
neurotoxicity do not coincide precisely (43-46). In 
(42). 
electrophysiologic studies, hippocampal pyramidal 
neurons show maximal responsiveness to NMDA at 
PND 5 to 9 (47), and immature hippocampal neuron 
NMDA receptor / channels are less susceptible to 
blockade by Mg++ and more sensitive to modulation 
by glycine (48,49) or polyamines (14). Alternatively, 
some populations of immature neurons may be less 
able to buffer EAA-induced increases in free intra- 
cellular calcium, due to immaturity of mechanisms 
such as the calcium-binding protein calbindin D28k 
(50). 
EAA and Perinatal Hypoxic-Ischemic Brain 
Injury 
Several complementary experimental approaches 
have been used to examine the role of EAA in the 
pathogenesis of perinatal hypoxic-ischemic brain 
injury. An experimental model of perinatal stroke, 
elicited by unilateral carotid ligation and subsequent 
timed exposure to moderate hypoxia in immature 
rats, has been used extensively in these studies (51). 
In seven day old rats, unilateral carotid ligation fol- 
lowed by exposure to an 8% oxygenlbalance nitro- 
gen atmosphere for 2 to 3.5 hours elicits ipsilateral 
forebrain injury. Neither ligation alone or hypoxia 
alone cause tissue injury; after ligation, superimposed 
hypoxia results in progressive ipsilateral ischemia 
(52). The threshold duration of 8% 0 2  exposure that 
results in tissue injury is close to 1.5 hours. Overall, 
the severity of injury then increases with increasing 
duration of hypoxia. However, in this preparation, 
for unexplained reasons, there is considerable vari- 
ability in the severity and histopathologic features of 
injury in lesioned animals. In this perinatal model, 
the propensity for selective CA1 pyramidal cell dam- 
age which characterizes ischemic brain injury in 
adult models, is not observed. The features of hippo- 
campal histopathology are somewhat variable; of 
note, dentate gyrus neurons (considered relatively 
resistant to ischemic injury in adult brain) are often 
injured. 
Alterations in endogenous E M .  In this perinatal 
stroke model, the first evidence that focal ischemic 
brain injury disrupted the functional integrity of EAA 
synapses was the observation that in target areas 
for irreversible ischemic injury (striatum and hippo- 
campus) high-affinity glutamate uptake was acutely 
(and reversibly) suppressed during the evolution of 
injury. The importance of this finding was that it 
suggested a credible pathophysiologic mechanism 
that could account for acute accumulation of EAA in 
the synaptic cleft (53). 
Subsequent studies using in vivo microdialysis pro- 
vided more direct evidence that EAA accumulated 
in extracellular fluid (ECF) acutely with hypoxic- 
ischemic injury. In brain, ECF accumulation of neu- 
rotransmitters reflects regional synaptic concentra- 
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Figure 2 Glutamate antagonist neuroprotection: Both animals were subjected to right carotid ligation followed by three hours in 
8% oxygen on PND 7. Brains were removed on PND 12, sectioned and stained with Cresyl violet. Sections in panels 6 and D are 
from an animal pretreated with MK-801 1 mg/kg; sections in panels A and C are from a vehicle-treated control. Coronal-sections in 
panels A and B are at the level of the dorsal hippocampus; sections in panels C and D are a t  the level of the striatum. Note the 
reduction in size of the right hippocampus and striatum in the control animal (panels A,C), which is not discernible in the MK-801 
pretreated animal (panels 6.D). Scale bar - 1.6 mm. 
Reproduced from Reference 63, with permission from The American Heart Association. 
tions. Although accurate determination of concentra- 
tions of amino acids in interstitial fluid is extremely 
complex, with microdialysis, sequential changes in 
ECF content of amino acids can be readily estimated 
within defined brain regions. Synaptic accumulation 
of EAA could result from increased release (from 
neurotransmitter or metabolic pools) or suppression 
of neuronal and glial re-uptake. Calculated efflux 
rates provide estimates of regional ECF content of 
compounds of interest (e.g., for striatal glutamate 
1-2 pm). 
Using microdialysis, Hagberg et al. found that during 
acute global ischemia cortical and striatal extracel- 
lular fluid glutamate and aspartate concentrations 
rose markedly in fetal sheep (6). We developed a 
method for microdialysis in striatum and hippocam- 
pus of postnatal day 7 rats, and studied amino acid 
efflux in the perinatal rodent focal ischemia model. 
Striatal ECF amino acid efflux was stable over 3 to  4 
hours of sampling, and neither exposure to 8% oxy- 
gen or carotid ligation alone altered efflux (54). 
During the evolution of hypoxic-ischemic injury, 
increases (> 3-fold) in striatal glutamate efflux were 
detected, but the patterns differed from findings in 
adult brain. Glutamate efflux peaks were transient, 
and their timing varied (54). In contrast, in an adult 
rodent middle cerebral artery occlusion stroke model, 
striatal ECF glutamate concentration increased to 
> 6 0  times baseline 1 to 3 hours later (55). In hip- 
pocampus, using a slightly different experimental 
protocol, we found a progressive rise in glutamate 
efflux with increasing duration of hypoxia; the time 
of maximal efflux coincided with the threshold for 
ischemic injury and values returned to  baseline 
immediately post-hypoxia (56). To facilitate more 
detailed comparison of sequential changes in gluta- 
mate and glutamine efflux, for each animal, values 
were normalized, and expressed as a percentage base- 
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line (averaged from first three fractions) (Figure 1). 
Mean glutamate efflux peaked early in the second 
hour of hypoxia while glutamine efflux declined 
progressively. In contrast with glutamate, glutamine 
efflux declined gradually; the diverging trends sug- 
gest that systemic derangements such as dehydration 
were unlikely to account for the increase in gluta- 
mate efflux observed. The significance of the glu- 
tamine decline is uncertain; inhibition of the glial 
enzyme glutamine synthetase, which converts gluta- 
mate to glutamine, could account for both a reduc- 
tion in glutamine efflux and synaptic glutamate 
accumulation (57). Awareness of the role of endo- 
genous glycine in potentiating activation of NMDA 
receptors (58) prompted interest in analysis of gly- 
cine release; although no significant change in hip- 
pocampal glycine efflux was detected, our data 
revealed a trend towards increased glycine efflux in 
the second hour of hypoxia (56). Other investigators, 
using somewhat different dialysis methods in the 
same animal model, found that in cerebral cortex, 
ECF concentrations of glutamate and glycine rose 
acutely in hypoxic-ischemic cortex, and that while 
glutamate concentrations retum to normal post- 
hypoxia, glycine concentrations remain elevated 
In adult brain, aspartate efflux generally increases 
in parallel with changes in glutamate efflux dur- 
ing ischemia (5,60); however, we found no consis- 
tent increase in hippocampal aspartate efflux. This 
difference likely reflects lower synaptic concentra- 
tions of aspartate in immature brain; whether this 
developmental difference in EAA metabolism has 
pathophysiologic significance as to mechanisms of 
neuronal injury is unknown. 
It is important to acknowledge evidence suggesting 
that increased extracellular glutamate concentra- 
tions alone are not sufficient to produce brain injury 
(61,62). In the adult brain, the balance between 
excitatory and inhibitory amino acid neurotransmit- 
ter concentrations may correlate better with injury 
than extracellular glutamate alone (62). Of interest, 
in contra-distinction with studies in adult brain, 
baseline hippocampal GABA efflux was often unde- 
tectable in immature rodents, and no increases 
were detected with hypoxia-ischemia. Immaturity 
of GABAergic innervation may also be a contribu- 
ting factor to the pathophysiological differences in 
the evolution of ischemic neuronal injury between 
immature and adult brain. Factors such as intrin- 
sic variation in cellular susceptibility to excitotoxic 
injury and regional activity of endogenous neuro- 
modulatory compounds are also likely to play critical 
roles in determining the extent of ischemic neuronal 
damage. 
Neuroprotection with E A A  antagonists. The most 
convincing evidence that EAA contribute to the 
(59). 
pathogenesis of perinatal hypoxic-ischemic brain 
injury comes from neuroprotection studies with EAA 
antagonists. Several investigators have demonstrated 
that the non-competitive NMDA antagonist MK-801 
protects the immature rat brain from focal hypoxic- 
ischemic injury. McDonald et al. (7) found that in 
seven day old rats that underwent right carotid liga- 
tion and were treated with 1 mg/kg MK-801 immedi- 
ately before or 75 minutes after the onset of hypoxia 
(three hours total duration, in 8% oxygen) the severi- 
ty of brain injury was reduced, assessed by compari- 
son of cerebral hemisphere weights five days later, as 
compared with untreated litter-mates. The same 
treatment also attenuated the acute ipsilateral loss of 
EAA receptor binding observed 24 hours post-hypox- 
ia in hippocampus and striatum (63). MK-801 
administered immediately before or one hour into 
hypoxia (two hours total duration, in 8% oxygen) 
also prevented post-hypoxic-ischemic impairment in 
a learning and memory task at  30-days age and 
prevented hippocampal CA1 and CA3 pyramidal 
neuronal loss as assessed at 60-days age (64). 
Figure 2 compares the distribution of histopathology 
in two animals that underwent carotid ligation and 
hypoxic exposure on PND 7, one of which was treat- 
ed with MK-801; in the untreated animal, sacrificed 
on PND 12, there is prominent unilateral forebrain 
injury, with marked substance loss in striatum hippo- 
campus, and cortex. In this MK-801-treated animal 
there was considerable attenuation of injury; how- 
ever, it is important to consider that there is consid- 
erable variability in the efficacy of MK-801 against 
hypoxic-ischemic injury in this model. In contrast, 
the same dose of MK-801- (1 mg/kg) consistently 
completely prevents pure NMDA-induced injury 
(65). 
In a closely related injury model, in which low atmo- 
spheric pressure was combined with unilateral 
carotid ligation to elicit focal hypoxic-ischemic brain 
injury in the immature rat, treatment with MK-801 
1 mg/ kg, prior to hypobaric exposure, markedly 
decreased the severity of ipsilateral brain damage 
(66). In a model more closely approximating global 
perinatal cerebral hypoxia-ischemia (bilateral carotid 
ligation plus one hour in 8% oxygen), Hattori et al. 
(67) demonstrated attenuation of cortical and striatal 
damage by administration of MK-801 10 mgfkg 
shortly after hypoxia, and complete prevention of 
damage in survivors if the same high dose was 
administered immediately before hypoxia (but with 
increased acute mortality). 
In adult animaIs, it has been suggested that the bene- 
ficial effects of MK-801 were attributable to MK-801- 
induced hypothermia (18). In the hypobaric-ische- 
mia model, a mild elevation in body temperature 
was associated with MK-801 treatment (66); neither 
McDonald et al. (7) or Ford et al. (64) reported body 
or brain temperature measurements. However, when 
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temperature was monitored in unlesioned seven day 
old rats after treatment with the same dose (1 mg/kg) 
of MK-801, only slight reductions were observed 
(0.98 * 0.08 "C, n=4) (68),  and in lesioned seven day 
old rats pretreated with MK-801, 10 mg/kg, rectal 
temperature over a 24 hour period did not differ 
from controls (69). Thus, in immature rodents, hypo- 
thermia cannot account for neuroprotection. 
The efficacy of other EAA antagonists has also been 
tested in the same model. Treatment with kynu- 
renate, which blocks both NMDA and non-NMDA 
receptors, prior to hypoxia, reduced cerebral edema 
(70); administration of the same dose of kynurenate 
after hypoxia-ischemia attenuated ipsilateral hemi- 
sphere weight loss, an accurate measure of the sever- 
ity of brain injury (71). Similarly, treatment with 
dextromethorpan, another non-competitive NMDA 
antagonist, prior to hypoxia, reduced the incidence 
of frank ipsilateral cerebral infarction (72). 
A recent study in a model of incomplete global cere- 
bral ischemia in the piglet yielded different results; 
MK-801 provided incomplete neuroprotection, limit- 
ed to the hippocampus (73). Differences in the 
pathophysiology of ischemic injury (e.g., global or 
focal), and drug metabolism could account for such 
discrepancies in neuroprotective efficacy in different 
experimental paradigms. 
No published studies have examined the neuro- 
protective effficacy of AMPA antagonists such as 
NBQX in perinatal ischemic brain injury. Optimal 
protective regimens for cerebral ischemia may 
require blockade of both NMDA and non-NMDA 
receptors (74), and such combination therapies have 
not yet been evaluated. 
Conclusions 
Thus, in perinatal rodent brain there is strong evi- 
dence that EAA play a major role in the pathogenesis 
of focal ischemic injury. To what extent these obser- 
vations are relevant to treatment of ischemic brain 
injury in human infants remains uncertain. In con- 
sidering treatment with EAA antagonists, an impor- 
tant issue that must be acknowledged is their 
potential detrimental effects in the developing brain. 
Since EAA play critical roles in normal synaptic mat- 
uration, EAA blockade could disrupt normal develop- 
mental processes, and the adverse impact of EAA 
antagonists will require careful evaluation before 
such drugs come into use clinically. Drugs that block- 
ed excessive EAA release, or enhanced re-uptake 
might provide neuroprotection more selectively than 
receptor antagonists. Another potentially important 
pharmacologic strategy that must be explored is the 
development of combination therapies, targeting 
multiple components of the complex biochemical 
cascade that leads to irreversible ischemic injury, 
including EAA receptor over-activation, concurrently. 
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